首页> 外国专利> EMPLOYING HUMAN ADIPOSE-DERIVED STEM CELLS TO PROPAGATE SERUM-DERIVED HEPATITIS C VIRUS AND USE THEREOF

EMPLOYING HUMAN ADIPOSE-DERIVED STEM CELLS TO PROPAGATE SERUM-DERIVED HEPATITIS C VIRUS AND USE THEREOF

机译:运用人源性干细胞繁殖血清来源的丙型肝炎病毒并加以利用

摘要

Hepatitis C virus replication at extrahepatic sites has been suggested; however, complete viral replication has only been confirmed in hepatocytes. Here we show that human adipogenic DLK-1+ stem cells (hADSC) freshly isolated from HCV-infected individuals contained viral transcripts, replication intermediates and viral antigens in vivo, and viral transcripts increased in supernatants upon prolonged ex vivo culture. Furthermore, naive hADSC isolated from HCV (−) individuals support complete replication of clinical isolates in vitro, and the infection is donor-nonspecific for cells and cross-genotypic for viruses. Viral infection/replication is mediated through CD81, LDL-R, SR-B1, EGFR, Apolipoprotein E, occludin, claudin-1, NPC1L1 and diacylglycerol acetyltransferase-1, and can be inhibited by anti-viral drugs. In addition, the physical properties of hADSC-propagated viral particles resemble clinical isolates more than JFH1/HCVcc, and viruses propagated by in vitro infected hADSC are infectious to primary human hepatocytes. Therefore, hADSC are an in vivo HCV reservoir and represent a novel venue of clinical virus-host interaction. hADSC can also be exploited as a physiologically relevant primary cell culture system to propagate clinical isolates.
机译:有人建议在肝外部位复制丙型肝炎病毒。但是,只有在肝细胞中才能确认病毒的完全复制。在这里,我们显示新鲜分离自HCV感染个体的人成脂性DLK-1 + 干细胞(hADSC)在体内含有病毒转录本,复制中间体和病毒抗原,并且长时间延长上清液中的病毒转录本会增加体内培养。此外,从HCV(-)个体中分离出的幼稚hADSC支持体外临床分离株的完全复制,并且感染对细胞是非特异性的,对于病毒是跨基因型的。病毒感染/复制是通过CD81,LDL-R,SR-B1,EGFR,载脂蛋白E,occludin,claudin-1,NPC1L1和二酰基甘油乙酰转移酶-1介导的,可以被抗病毒药物抑制。此外,hADSC传播的病毒颗粒的物理特性比JFH1 / HCVcc更类似于临床分离株,并且由体外感染的hADSC传播的病毒对原代人肝细胞具有感染性。因此,hADSC是体内HCV贮藏库,代表了临床病毒-宿主相互作用的新场所。 hADSC也可以用作生理相关的原代细胞培养系统,以繁殖临床分离株。

著录项

  • 公开/公告号US2018023058A1

    专利类型

  • 公开/公告日2018-01-25

    原文格式PDF

  • 申请/专利权人 FRONTIER BIO-DRUG DEVELOPMENT LIMITED;

    申请/专利号US201515541913

  • 发明设计人 CHEN-LUNG LIN;

    申请日2015-01-07

  • 分类号C12N7;C12N5/0775;G01N33/50;C12Q1/70;G01N33/576;

  • 国家 US

  • 入库时间 2022-08-21 13:01:59

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号